Phase 1 ALS trial is first to test antisense treatment of neurodegenerative disease: No serious adverse effects reported




The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis -- blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease -- may be a first step towards a new era in the treatment of such disorders.

Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/p...

Miércoles, 3 de Abril 2013
Jueves, 1 de Enero 1970
1

1 1
Otros artículos de esta sección